EA201992840A3 - Конструкции варианта sirp-альфа и их применение - Google Patents

Конструкции варианта sirp-альфа и их применение

Info

Publication number
EA201992840A3
EA201992840A3 EA201992840A EA201992840A EA201992840A3 EA 201992840 A3 EA201992840 A3 EA 201992840A3 EA 201992840 A EA201992840 A EA 201992840A EA 201992840 A EA201992840 A EA 201992840A EA 201992840 A3 EA201992840 A3 EA 201992840A3
Authority
EA
Eurasian Patent Office
Prior art keywords
sirp
tumor
constructions
application
variant constructs
Prior art date
Application number
EA201992840A
Other languages
English (en)
Other versions
EA201992840A2 (ru
Inventor
Лаура Деминг
Кори Гудман
Хайме Понс
Бан Жанет Сим
Мария Врлйик
Original Assignee
АЭлЭкс ОНКОЛОДЖИ ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АЭлЭкс ОНКОЛОДЖИ ИНК. filed Critical АЭлЭкс ОНКОЛОДЖИ ИНК.
Publication of EA201992840A2 publication Critical patent/EA201992840A2/ru
Publication of EA201992840A3 publication Critical patent/EA201992840A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к композициям и способам получения конструкций варианта SIRP-, включающих варианты SIRP-. Конструкции варианта SIRP- могут быть сконструированы различными способами для ответа на средовые факторы, такие как рН, гипоксия и/или присутствие опухоль-ассоциированных ферментов или опухоль-ассоциированных антигенов. Конструкции варианта SIRP- могут быть использованы для лечения различных заболеваний, таких как рак, предпочтительно солидной опухоли или гематологической злокачественной опухоли.
EA201992840A 2015-08-07 2016-08-03 Конструкции варианта sirp-альфа и их применение EA201992840A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562202779P 2015-08-07 2015-08-07

Publications (2)

Publication Number Publication Date
EA201992840A2 EA201992840A2 (ru) 2021-07-30
EA201992840A3 true EA201992840A3 (ru) 2021-11-30

Family

ID=77443263

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992840A EA201992840A3 (ru) 2015-08-07 2016-08-03 Конструкции варианта sirp-альфа и их применение

Country Status (1)

Country Link
EA (1) EA201992840A3 (ru)

Also Published As

Publication number Publication date
EA201992840A2 (ru) 2021-07-30

Similar Documents

Publication Publication Date Title
GB2532619A (en) Sirp-Alpha Variant Constructs And Uses Thereof
EA201691384A2 (ru) Конструкции варианта sirp-альфа и их применение
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
MX2022008184A (es) Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer.
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
EA201891366A1 (ru) Гуманизированные антитела против cd73
EA202091540A1 (ru) Антитела к lilrb2
NZ738008A (en) Tigit-binding agents and uses thereof
PH12017500890A1 (en) Antibody drug conjugates
MX2016016881A (es) Anticuerpos que se unen a axl.
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
PH12020550035A1 (en) Universal abt compounds and uses thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2022002682A (es) Anticuerpos anti-cd73.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
EA201992840A3 (ru) Конструкции варианта sirp-альфа и их применение
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.